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Abstract
Prednisone is often used for the treatment of autoimmune and inflammatory diseases but they suffer from variable
therapeutic responses and significant adverse effects. Serum biological markers that are modulated by chronic
corticosteroid use have not been identified. Myasthenia gravis is an autoimmune neuromuscular disorder caused by
antibodies directed against proteins present at the post-synaptic surface of neuromuscular junction resulting in weakness.
The patients with myasthenia gravis are primarily treated with prednisone. We analyzed the metabolomic profile of serum
collected from patients prior to and after 12 weeks of prednisone treatment during a clinical trial. Our aim was to identify
metabolites that may be treatment responsive and be evaluated in future studies as potential biomarkers of efficacy or
adverse effects. Ultra-performance liquid chromatography coupled with electro-spray quadrupole time of flight mass
spectrometry was used to obtain comparative metabolomic and lipidomic profile. Untargeted metabolic profiling of serum
showed a clear distinction between pre- and post- treatment groups. Chronic prednisone treatment caused upregulation of
membrane associated glycerophospholipids: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, 1, 2-
diacyl-sn glycerol 3 phosphate and 1-Acyl-sn-glycero-3-phosphocholine. Arachidonic acid (AA) and AA derived pro-
inflammatory eicosanoids such as 18-carboxy dinor leukotriene B4 and 15 hydroxyeicosatetraenoic acids were reduced.
Perturbations in amino acid, carbohydrate, vitamin and lipid metabolism were observed. Chronic prednisone treatment
caused increase in membrane associated glycerophospholipids, which may be associated with certain adverse effects.
Decrease of AA and AA derived pro-inflammatory eicosanoids demonstrate that immunosuppression by corticosteroid is via
suppression of pro-inflammatory pathways. The study identified metabolomic fingerprints that can now be validated as
prednisone responsive biomarkers for the improvement in diagnostic accuracy and prediction of therapeutic outcome.
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Introduction
Corticosteroids are used for chronic treatment of numerous
inflammatory and autoimmune disorders as well as diseases
considered to have a significant inflammatory component [1–3].
Although effective for many conditions, their use is compromised
by poor side effect profiles, which vary widely among patients [4].
To date, serum biological markers that are clearly modulated by
chronic corticosteroid use have not been identified. Biomarkers are
useful in medical practice as predictors of therapeutic effect or
correlate to adverse effects. However, the discovery of these key
determinants requires linkage to clinical trials to obtain samples.
The effort is hampered by limited number of opportunities to
obtain specimens, cost of collection, and lack of foresight by
clinical trial organizers, thereby reducing the number of biological
samples obtained from a homogenous population and treatment.
Myasthenia gravis (MG) is a chronic, autoimmune neuromus-
cular disorder caused by antibodies directed at proteins concen-
trated on the post-synaptic surface of the neuromuscular junction,
primarily the nicotinic acetylcholine receptors. The primary
treatment provided for patients with MG is prednisone adminis-
tered for several months at high doses [5]. Typical treatment
regimens result in at least 30 percent of patients having adverse
effects due to dose and duration of administration [6,7]. The
sources of the variation in response to prednisone and suscepti-
bility to complications among patients are not known and
biological markers that are predictors of adverse effects or
improvement have not been identified.
Variation in the response to pharmacologic agents have
highlighted the necessity for individualizing drug therapy to select
patients who are most likely to respond to treatment, to minimize
the occurrence of adverse drug reactions, and to maximize the
desired therapeutic effect. Metabolomics provides a snapshot of all
the metabolites present at a given point of time, offers the
opportunity for unbiased discovery of disease mechanisms, and
identification of possible biomarkers of therapeutic responsiveness
[8]. Metabolomic studies can assess therapeutic responsiveness
from the perspective of a global alteration in metabolism, which is
ultimately dependent on specific disease pathophysiology, individ-
ual subject variation (influenced by genetics and environmental
factors), and drug mechanism. This technique has been used for
determining drug response phenotype of several diseases [9].
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Lu et al., used a serum metabolomic approach as a diagnostic
measure to classify patients with various grades of MG [10] and
identified a set of metabolites that could differentiate patients from
healthy subjects. In this study, we used serum samples from fifteen
patients for metabolomic analysis obtained during the course of a
randomized clinical trial in which sampling was taken before
treatment and after 20 mg of prednisone per day for treatment of
generalized MG [11]. Our purpose was to explore the effect of
prednisone treatment on metabolomic profile and identify
treatment-responsive metabolites that could be translated to
clinical applications. Ultra-performance liquid chromatography
coupled with electro-spray quadrupole time of flight mass
spectrometry (UPLC-ESI-QTOF-MS) was used to obtain com-
parative metabolomic and lipidomic profile of subject sera.
Materials and Methods
Ethics statement
The sera used in this investigation are de-identified samples
from a clinical trial performed by the Muscle Study Group
(NCT00683969). Internal Review Board approval was obtained
by all investigators of the Muscle Study Group to obtain sera for
investigative studies. The George Washington University Internal
Review Board also approved the use of samples.
Sample Characteristics
All samples were obtained during the course of a clinical trial
performed by the Muscle Study Group (ClinicalTrials.gov
identifier NCT00683969) [11] and drawn as part of routine
phlebotomy to evaluate acetylcholine receptor antibody levels at
study initiation and after 12 weeks of prednisone treatment.
Subjects had been given no specific instructions regarding fasting
or timing of the blood sampling. Serum was isolated and stored at
280uC. The subjects had mild to moderate MG with serum
Figure 1. Prednisone treatment of MG patients shows clear segregation of metabolite patterns in positive and negative ionization
mode. A) Two dimensional accuracy plot for 750 features interrogated in positive ionization mode using Random Forests (RF). It shows clear
separation of the two groups T1 (before treatment in blue) and T2 (after treatment in red). X-axis denotes inter-class class separation and Y-axis shows
intra-class variability B) Accuracy plot for RF in positive ionization mode shows 100% accuracy. C) Two dimensional accuracy plot for 703 features
interrogated in negative ionization mode using Random Forests (RF). It shows clear separation of T1 and T2. D) Accuracy plot for RF in negative
ionization shows 100% accuracy. E) Heat map visualization of the top 50 discriminating features between T1 and T2 in positive mode. F) The top 50
discriminating features between T1 and T2 in negative mode.
doi:10.1371/journal.pone.0102635.g001
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antibodies to the acetylcholine receptor antibodies. All patients at
study entrance were naı¨ve to immunosuppressive therapy for at
least 3 months. For this study we used 15 serum samples of the
patients obtained at trial initiation prior to treatment and then at
12 weeks of treatment with prednisone. Subjects were followed in a
double blind fashion and subject to validated clinical outcome
assessments including adverse effect assessment. Individual patient
characteristics were not available to the present investigators
because of the established informed consent agreement during the
trial. Seventy-seven percent of patients improved and about
twenty-five percent complained of adverse effects [11]. By clinical
trial exclusion criteria, no subject had evidence of significant
systemic illness at onset of the trial and at the end of 12 weeks of
treatment the adverse effect reports did not indicate hepatic or
renal dysregulation.
Metabolite extraction
Sample processing and initial analysis was performed blinded to
the treatment status. The serum samples were thawed from 2
80uC storage on ice. For metabolite extraction, 175 mL of 66%
acetonitrile (in water) containing internal standards [10 mL of
debrisoquine (1 mg/mL) and 50 mL of 4, nitro-benzoic acid
(1 mg/mL)] were added to 25 mL of serum. The samples were
incubated on ice for 15 minutes and centrifuged at 14,000 rpm at
4uC for 20 minutes. The supernatant was transferred to a fresh
tube and dried under vacuum. The dried samples were re-
suspended in 100 mL of solvent A (98% water and 2% acetonitrile)
for UPLC-ESI-QTOF-MS analysis.
UPLC-ESI-QTOF-MS based data acquisition
Each sample (5 mL) was injected onto a reverse-phase
5062.1 mm BEH 1.7 mm C18 column using an Acquity UPLC
system (Waters Corporation, USA). The gradient mobile phase
comprised of water containing 0.1% formic acid solution (A) and
acetonitrile containing 0.1% formic acid solution (B). Each sample
was resolved for 10 min at a flow rate of 0.5 ml/min. This
approach has been extensively used for metabolomic profiling of
biofluids; UPLC gradients conditions and the mass spectrometry
parameters have been described in details [12–14]. The UPLC
gradient consisted of 100% A for 0.5 min then a ramp of curve 6
to 60% B from 0.5 min to 4.5 min, then a ramp of curve 6 to
100% B from 4.5 to 8.0 min, a hold at 100% B until 9.0 min, then
a ramp of curve 6 to 100% A from 9.0 min to 9.2 min, followed by
a hold at 100% A until 10 minutes. The column eluent was
introduced directly into the mass spectrometer by electrospray.
The column temperature was maintained at 40uC. Mass
spectrometry was performed on a Quadrupole-time-of-flight mass
spectrometer operating in either negative or positive electrospray
ionization mode with a capillary voltage of 3.2 KV and a sampling
cone voltage of 35 V. The desolvation gas flow was 800 L/h and
the temperature was set to 350uC. The cone gas flow was 50 L/h,
and the source temperature was 150uC. The data was acquired in
the V mode with scan time of 0.3 seconds, and inter-scan delay at
0.08 seconds. Accurate mass was maintained by infusing
sulfadimethoxine (311.0814 m/z) in 50% aqueous acetonitrile
(250 pg/mL) at a rate of 30 mL/min via the lockspray interface
every 10 seconds. Data were acquired in centroid mode from 50 to
850 m/z mass range for TOF-MS scanning, in duplicates
(technical replicates) for each sample in positive and negative
ionization mode and checked for chromatographic reproducibility.
Figure 2. Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA) of determinants in positive and negative ionization
mode. A) Scores plot obtained from OPLS-DA model of T1 and T2 in positive ionization mode shows inter-group separation B) OPLS-DA loadings S-
plot comparing features from T1 and T2 in positive ionization mode. C) Score plot obtained from OPLS-DA model of T1 and T2 in negative ionization
mode shows inter-group separation. D) OPLS-DA loadings S-plot comparing features from t1 and t2 in negative ionization mode. Each spot in S-plot
corresponds to a feature with characteristic m/z ratio and retention time. The metabolites marked in red were treated as putative bio-markers for the
therapy and characterized later.
doi:10.1371/journal.pone.0102635.g002
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For all profiling experiments, the sample queue was staggered by
interspersing samples of the two groups to eliminate bias. The
coefficient of variance (CV) for serum samples was found to be ,
10%. The profiling experiment was repeated thrice to check
experimental reproducibility.
For untargeted metabolomics profiling, the extraction buffer
was spiked with a known concentration of internal standards (4,
nitrobenzoic acid in negative mode and debrisoquine in positive
mode) to account for variability in the extraction procedure and
for inconsistencies during the MS acquisition. Relative quantita-
tion was achieved for molecular ions using the UPLC-QTOF
system by taking a ratio of normalized intensity of the respective
study groups for the ions of interest [15–17]. In order to ensure
data quality and reliability, a test mix of standard metabolites was
injected at the beginning and at the end of the batch and the
extracted ion chromatograms were evaluated for mass accuracy
and sensitivity with respect to intensity for the given standards
[18].
Data Pre-processing
Centroided and integrated UPLC-TOFMS data were pre-
processed using the XCMS [19] software and normalized to the
ion intensity of respective internal standards (4, nitrobenzoic acid
in the negative mode and debrisoquine in the positive mode). The
resultant data containing mass/charge (m/z) value, retention time
(rt) and peak intensity were subjected to multivariate data analyses
between the pre- (T1) and post- (T2) treatment groups to delineate
significantly altered metabolites.
Statistical analysis
Prior to statistical analyses, the data were Pareto scaled which is
the recommended method for LCMS data since both medium and
small features in the data are important. We used two independent
multivariate analysis methods as a means of ‘‘in silico’’ validation;
Orthogonal Partial Least Squares Discriminant Analysis (OPLS-
DA) models [20] and Random Forests methods [21]. The OPLS-
DA models were run using SIMCA-P+ version 12 (Umetrics, Inc.)
and the Random Forests methods were run using several R
packages with specific use of the G plot library for heat map
graphics within R. 2.11.0 [22]. Quantitative descriptors of model
quality for the OPLS-DA models included R2 = 0.95 (explained
variation of the binary outcome) and Q2 = .74 (cross-validation
based predicted variation of the binary outcome) using two
components. We used score plots to visualize the discriminating
properties of the OPLS-DA models, and also S-plots for putative
biomarker identification by visualization of the OPLS-DA loadings
on the predictive score. Selection of features based on the OPLS-
DA model used a p (corr) cut-off of 0.8, as reported previously
[23,24], which led to selection of the top 50 features. Further, we
chose cross validation over permutation test since our data sets
(number of samples in each group) were small. In our analyses, we
employed 10-fold cross validation method, to determine the
Table 1. Significantly altered metabolites of glycerophospholipid pathway.
Metabolite1 ID2 m/z3 RT4 (min) Mode5 T2/T16 Fold Change (+/2SEM) p-value7
PC(18:1/18:1) HMDB00593 786.5977 9.11 Pos 12.63 (1.98) q 7.4 E-09
PC(18:3/P-8:1) HMDB08194 766.5699 8.5 Pos 8.72 (1.26) q 6.9 E-06
PC(16:0/18:3) HMDB07975 756.5522 8.16 Pos 23.84 (6.90) q 7.5 E-10
PC(20:0/14:1) HMDB08263 760.5822 9.01 Pos 20.09 (3.95) q 2.2 E-07
PC(20:5/20:2) HMDB08506 832.5807 8.88 Pos 8.44 (1.77) q 2.8 E-10
PE(20:1/18:1) HMDB09257 772.5844 8.79 Pos 17.25 (2.87) q 7.2 E-09
PE(20:1/0:0) HMDB11512 506.3229 4.97 Neg 11.68 (2.78) q 3.5 E-10
PE(P-8:1/18:2) HMDB11409 724.5314 8.71 Neg 3.33 (0.33) q 3.2 E-08
PE(20:4)/P-8:1) HMDB09413 748.5297 8.61 Neg 5.26 (0.57) q 8.5 E-09
PE(18:2/20:4) HMDB09103 762.5131 8.26 Neg 6.40 (0.59) q 1.8 E-08
PS(O-0:0/17:1) 790.6028 8.14 Pos 20.27 (5.53) q 7.2 E-10
PS(P- 8:0/20:4) 796.5441 7.3 Pos 19.95 (6.78) q 3.7 E-08
PS(19:0/0:0) 538.3145 4.45 Neg 38.97 (11.24) q 2.4 E-10
PS(17:2/22:2) 824.5455 8.08 Neg 12.70 (3.29) q 2.1 E-12
PS(18:3/21:0) 826.5605 8.35 Neg 4.76 (1.64) q 3.0 E-12
LysoPC(15:0) HMDB10381 480.3086 4.79 Neg 15.74 (4.81) q 9.3 E-12
LysoPC(20:3) C04230 546.3529 4.78 Pos 9.51 (6.63) q 5.2 E-07
LysoPC(18:1) C04230 522.3543 4.97 Pos 2.12 (0.39) q 3.9 E-03
LPA (0:0/16:0) C00416 409.2348 5.21 Neg 11.41 (5.14) q 3.3 E-03
Phospho choline C00588 184.0742 7.58 Pos 0.89 (0.05) Q 2.40E-02
1Glycerophospholipids (Phosphatidylcholine: PC, Phosphatidylethanolamine: PE, Phosphatidylserine: PS, lyso PC: 1-Acyl-sn-glycero-3-phosphocholine; LPA: 1,2-Diacyl-sn
glycerol 3 phosphate or Phosphatidate).
2Metabolite ID obtained from Human Metabolome Data Base and KEGG.
3mass/charge value.
4retention time.
5Ionization modes.
6Fold changes between post-treatment (T2) and pre-treatment (T1) groups with +/2 SEM.
7The p-value as determined by student’s t-test.
doi:10.1371/journal.pone.0102635.t001
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optimal number of components in our model. The features
selected via OPLS-DA together with those selected as the top 50
discriminating features by the Random Forests methods were used
for accurate mass based search. Top 50 metabolites that are
differentially expressed in the two groups were selected and heat
map was generated for both positive ionization and negative
ionization data. We also performed a 2-tailed t-test on the entire
data set and selected metabolites with p,0.05 for further
evaluation. We used Graph Pad Prism 5 for depicting fold
changes of selected metabolites as scatter plots.
Metabolite identification
The metabolites were putatively identified by accurate mass
based search using ‘‘MetaboSearch’’ (http://omics.georgetown.
edu/MetaboSearch.html), a web-based software tool that enables
simultaneous mass-based search against the four major databases,
Human Metabolome DataBase (HMDB), Madison Metabolomics
Consortium Database (MMCD), Metlin, and LIPID MAPS [25].
The output of the search provided an integrated table with m/z
value of each feature, their name, formula, exact mass and fold
change in expression. Based on this information, their putative
identification was determined.
Metabolomic Analysis
Kyoto Encyclopedia of Gene and Genome (KEGG) Pathway
program (http://www.genome.jp/kegg/pathway.html) was used
to identify the metabolic pathways that were deregulated in our
study. We selected a few of the specific upstream or downstream
components of each of the pathways and searched for their
presence in our original data set by comparing their predicted
mass values. This approach of ‘‘in-silico’’ validation was used to
delineate the pathway involved.
Validation
The metabolite identifications were confirmed by comparing
the retention time under the same chromatographic conditions
and by matching the fragmentation pattern of the parent ion from
the biological sample to that of the standard metabolite using
tandem mass spectrometry (UPLC-TOFMS/MS).
Results
Serum metabolomic analysis
Untargeted serum metabolomic profiling yielded 750 features in
positive ionization mode and 703 features in negative ionization
mode. Two dimensional accuracy plots for these features using
Random Forests (RF) shows clear segregation of the two groups,
T1 (before treatment) and T2 (after treatment) in both the
ionization modes (Figures 1A and 1C). Accuracy plot shows 100%
accuracy of class separation (Figures 1B and 1D). The dataset was
filtered for metabolites with p-value #0.05. 50 metabolites that
segregated baseline from post-treatment samples were analyzed
using RF and heat maps were plotted (Figures 1E and 1F). The
putative identities of each of these metabolites have been tabulated
in the supplemental data (Tables S1 and S2). Orthogonal Partial
Least Squares Discriminant Analysis (OPLS-DA) score plots were
Figure 3. Prednisone treatment causes perturbation in Glycerophospholipid metabolism. The figure represents glycerophospholipid
metabolism pathway from KEGG resource showing the metabolites that change significantly in MG patients after prednisone treatment. The
metabolites marked in red shows increase in T2 (post-treatment) population and the ones marked in green shows decrease in abundance in T2. The
figure is a screen shot from, http://www.genome.jp/kegg-bin/show_pathway?map=map00564&show_description= show.
doi:10.1371/journal.pone.0102635.g003
Effect of Corticosteroid Treatment
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done using SIMCA-P+ (Figures 2A and 2C). The score plots
resulted in an unambiguous inter-group separation. The loading
plots (S-Plot) identified the metabolites with significant differences
in the abundance in the two study groups (Figures 2B and 2D).
The chemical formula calculations and putative identification of
all these features were performed by an accurate mass based
search by using the MetaboSearch software. Some of these
metabolites were unambiguously identified using tandem MS by
matching fragmentation pattern against standard compounds as
described in the Validation section.
Metabolomic profiling of serum samples showed statistically
significant changes in glycerophospholipid metabolism (p#0.05),
in response to prednisone treatment. Within the glyceropho-
spholipid metabolism pathway, phosphatidylcholine (PC) (4 to 11
fold; p = 6.89E-06), phosphatidylethanolamine (PE) (2 to 12 fold;
p = 3.23E-08), phosphatidylserine (PS) (2 to 10 fold; p = 3.73E-08),
1,2-diacyl-sn glycerol 3 phosphate (phosphatidate, LPA) (2.12 fold;
p = 3.27E-03), and 1-acyl-sn-glycero-3-phosphocholine (Lyso PC)
(1.73 to 6.25 fold; p = 3.94E-3) showed increase in expression
(Figures 3; Table 1). Phosphocholine demonstrated a decrease of
0.87 fold (p = 2.40E-02).
Arachidonic acid metabolism and related anti-inflammatory
pathway was found to be downregulated by prednisone treatment
(Figures 4 and 5, Table 2). Downregulation of AA (0.42 fold;
p = 4.46E-04), 18-carboxy dinor leukotriene B4 (0.77 fold;
p = 2.5E-04) and 15 hydroxyeicosatetraenoic acids (15HETE)
(0.34 fold; p = 1.01E-03) was observed. We have identified a
metabolite with m/z value 369.2254 in negative ionization mode
which corresponds with thromboxane B2 and 6-Keto prostaglan-
din F1alpha. Determining the exact identity of the metabolite was
beyond the scope of the study but both the putative metabolites
are present downstream of cox1/cox2 pathway of prostaglandin
G2 metabolism. Decrease in the expression of the above
mentioned metabolite by 0.29 fold (p = 7.84E-05) was observed.
Other metabolites that showed statistically significant alterations
in expression were L-phenylalanine (0.66 fold; p = 7.63E-04), O-
acetylserine (0.55 fold, p = 1.45E-02) and N2-acetyl-L-ornithine
(0.72 fold; p = 1.24E-02); involved in amino acid metabolism.
Citric acid cycle demonstrated perturbation, as noted by decrease
in aconitate ion (0.731; p = 6.43E-6) and 3-epihydroxy-29-deox-
ymugineic acid (0.67 fold; p = 3.78E-03). Vitamin E succinate
(1.41 fold; p = 1.39E-02) showed an increase and 3-deoxyvitamin
D3 (0.49 fold; p = 1.86E-05) showed a decrease in abundance in
Figure 4. Downregulation of Arachidonic Acid (AA) and pro-inflammatory pathways. The figure represents arachidonic acid metabolism
pathway from KEGG resource showing the metabolites that are downregulated in MG patients in response to prednisone treatment. The figure is a
screen shot from, http://www.genome.jp/kegg-bin/show_pathway?map=map00590&show_description= show.
doi:10.1371/journal.pone.0102635.g004
Figure 5. Metabolic changes in the serum samples of MG
patients in response to prednisone treatment. Schematic outline
summarizing the significant changes observed in the metabolic
pathways. The upregulated metabolites identified in the serum samples
have been marked in red and the downregulated metabolites have
been marked in green. Membrane glycerophospholipids are upregu-
lated in response to prednisone treatment. Arachidonic Acid (AA)
metabolism via cyclooxygenase (COX) and lipoxygenase (LOX) pathway
is downregulated causing reduction of pro-inflammatory metabolites.
PG, Prostaglandin, TX, Thromboxane; LT, Leukotriene; HETE, Hydroxy-
eicosatetraenoic acid; HpETE, Hydroperoxy-eicosatetraenoic acid; PLA,
Phospholipase A.
doi:10.1371/journal.pone.0102635.g005
Effect of Corticosteroid Treatment
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e102635
the post-treatment group. Hydroxyspheroidenone, involved in
carotenoid biosynthesis, was increased by 6.27 fold (p = 7.25E-08)
(Table 2).
To further assess variation in fold changes of the sample sets, we
produced scatter plots depicting the mean fold changes (6
standard error of the mean) (Figure S1). For each of the 32
metabolites, the 15 sets demonstrated the same increase or
decrease in fold change trend in for all 32 metabolites illustrated.
Validation
Validation of PC, PE and AA was done by UPLC-TOFMS/MS
by comparing the fragmentation pattern of the standards with the
ones present in the samples. We matched the parent and the
daughter ions and confirmed the presence of PC (m/z 184.07,
185.07, 786.59, 787.60, 788.60), PE (m/z 184.07, 185.07, 772.58)
and AA (m/z 259.24, 303.23) in our samples. See Figures S2, S3,
and S4.
Discussion
Untargeted metabolic profiling of serum obtained from patients
before and after 12 weeks of prednisone treatment demonstrated
an unambiguous metabolic signature of chronic glucocorticoid
treatment. Despite expected human variation on metabolism [26],
there was a uniform and significant effect across subjects with
treatment as determined by several methods of analysis. Indepen-
dent multivariate statistical approaches clearly discriminated pre-
and post-treatment samples as did the Random Forests method
with complete separation of the groups with 100% accuracy with
respect to the discriminating metabolites. Heat maps of the top 50
differentially expressed metabolites also confirmed the clear
distinction between the pre- and post-treatment groups. Orthog-
onal Partial Least Squares Discriminant Analysis (OPLS-DA) was
performed. The OPLS-DA score plots clearly showed inter-group
segregation of samples from subjects who were prednisone-naı¨ve
and after 12 weeks of prednisone therapy. Assessment of fold
changes identified metabolites with a significant fold change (p,
0.05) with prednisone treatment demonstrated overall consistency
with expected biological variability across subjects; however,
outliers existed with significantly greater fold changes (Figure
S1). Taken together the observations support a uniform metabo-
lomic signature for chronic prednisone treatment.
Detailed analysis of the differentially regulated metabolites
revealed a significant change in glycerophospholipid metabolism.
Out of the top 50 discriminating features identified by RF and
represented in the heat maps, the majority were glyceropho-
spholipids (Table 1) signifying a strong impact of prednisone
treatment on glycerophospholipid metabolism. Corticosteroid
stimulated de novo synthesis of PC was observed in developing
lung and was associated with an increase in choline-phosphate
cytidylyltransferase activity [27]. Metabolomic analyses of bron-
choalveolar lavage fluid from dexamethasone treated, experimen-
tally induced asthma mouse model identified a similar increase in
PC level associated with a decrease in choline level [28]. We found
an increase in PC level and a decrease in intermediate
phosphocholine level (Figures 5). PC is a critical component of
the cellular membrane structure and is involved in lipid cell
signaling. The synthesis of PC can occur through two pathways;
CDP-choline pathway and PE methylation pathway [29]. The free
choline that is incorporated into PC is recycled back to the pool
through hydrolysis by the enzyme phospholipase D [30]. There is
an overall increase in PC, PE, PS and the intermediate DAG
(Figure 5) signifying that the entire PE-methylation pathway is up
regulated in response to prednisone treatment.
Apart from the increase in glycerophospholipid synthesis, a
significant decrease in AA and AA acid mediated pro-inflamma-
tory metabolites (Figure 5) was observed. Biologically active lipids
derived from AA have crucial roles in inflammation. Enzymatic
oxidation of AA is mediated by cyclooxygenase (COX), lipoxy-
genase (LOX) and P450 epoxygenase pathways generating
eicosanoids. COX enzymes metabolize AA to pro-inflammatory
prostaglandins (PGs) and thromboxanes (TXs). LOX mediated
pathway converts AA to leukotrienes (LTs), hydroxyeicosatetrae-
noic acids (HETEs) and lipoxins. Cytochrome P450 metabolizes
AA to cell signaling molecules such as epoxyeicosatrienoic acids,
HETEs and hydroperoxyeicosatetraenoic acids [31]. We found a
downregulation of AA and downstream eicosanoids of COX and
LOX pathways (Figure 5). Glucocorticoid inhibits prostaglandin
synthesis by inhibiting translation of PG synthase enzyme [32]. AA
release by phospholipase A2 (PLA2) is suppressed by glucocorti-
coids causing downregulation of prostaglandin and leukotriene
synthesis [32]. The results are in accordance with the previous
observations that immunosuppression by corticosteroid is via
suppression of these pro-inflammatory pathways. These alterations
were identified by serum metabolite analysis and have the
potential for being monitored to assess prednisone associated
alterations. Vitamin E succinate, which has anti-inflammatory
properties, was increased [33]. 3-Deoxyvitamin D3, an anti-
inflammatory metabolite, was reduced [34].
One action of glucocorticoids is to subvert metabolic pathways
away from pro-inflammatory AA synthesis, towards anti-inflam-
matory endocannabinoid synthesis pathway [35]. Though there
was an increase in phospholipids in response to prednisone
treatment, a decrease in AA and AA derived eicosanoids was
found. Endocannabinoids are local lipid messengers that induce
immune- and neuro-protection through the activation of G-
protein coupled cannabinoid receptors CB1 and CB2 [36].
Endocannabinoid pathway metabolites were not identified in the
metabolomic screening, but given their rapid and transient
production the present analysis cannot rule out their modulation
by chronic steroid treatment.
Corticosteroids induce muscle wasting through several mecha-
nisms including regulation of transcription, insulin sensitivity and
calcium concentrations [37]. Expected increase in proteogenic
amino acids were not observed in our study. However, reduction
in serum levels of L-phenylalanine, O-acetylserine and N2-acetyl-
L-ornithine was found indicating an imbalance in protein synthesis
and degradation [38].
A decrease in aconitate ion and 3-epihydroxy-29-deoxymugineic
acid shows deregulation of energy metabolism. Although pertur-
bation in citric acid cycle was noted, we expected a greater
number of metabolic pathways to be effected by prednisone
treatment. The inability of the metabolomic data bases to identify
every metabolite was a hindrance to the study. A number of
metabolites could not be identified by the data base search even
though they show a significant differential expression (Tables S1
and S2). Similarly, presence of certain metabolites in the samples
was unexpected. For example, a 6 fold increase in hydroxy-
spheroidenone, involved in carotenoid biosynthesis was found that
is not known to be related to steroid treatment or myasthenia
gravis.
The metabolomic profile reflects an individual’s immediate
physiological status. Our study demonstrates the potential of
metabolomics as a mean to discriminate and differentiate between
treated and untreated groups. The patients as a whole improved
due to the treatment. From our study we can clearly see a trend of
suppression of anti-inflammatory pathways by prednisone treat-
ment and an increase in membrane phospholipid synthesis
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(Figure 5). Altered PC metabolism has been suggested in asthma
with increase in level of PC and decrease in level of lyso-PC [39]
and Crohn’s disease where phospholipids were increased [40].
Differences in free choline and PC level in serum have been
associated with early markers of risk of having cardiovascular
disease (CVD) [41]. Our results suggest AA could be used to assess
treatment response and we hypothesize that PC levels may
correlated to tissue complication of steroid treatment.
No previous investigation has evaluated metabolomic modifi-
cations among humans with an autoimmune disorder treatment
with chronic prednisone administration. Despite the powerful
effects on human physiology of prednisone, we identified
metabolic alterations to be limited primarily to glyceropho-
spholipid and arachidonic acid pathway alterations. Our study is
a pilot study and a proof of principle. Further studies are
warranted for mechanistic study of drug-mediated effect and
molecular targets.
Supporting Information
Figure S1 Scatter plot representation of the fold chang-
es in selected metabolites in 15 patient samples. SEM
added. PC: phosphatidylcholine; PE: phosphatidylethanolamine;
PS: phosphatidylserine; LysoPC: lyso phosphatidylcholine; LPA:
phosphatidate; Ph Choline: phospho choline; AA: arachidonic
Acid; 15-HETE: hydroxyeicosatetraenoic acids; 18 COOH-LTB:
18-carboxy dinor Leukotriene B4; TXB2: Thromboxane B2/6-
keto PGF1alpha; L-Phe: L-Phenylalanine; OAS: O-Acetylserine;
N-Ac-Or: N2-Acetyl-L-ornithine; EpiHDMA: 3-Epihydroxy-29-
deoxymugineic acid; Vit D3:3-Deoxyvitamin D3; Vit E Succ:
Vitamin E Succinate; OH-Sp: Hydroxy-Spheroidenone.
(TIF)
Figure S2 Validation of Phosphatidyl choline in the
sample by MS/MS. Candidate marker was validated by
UPLC-TOF-MS/MS. Q1 to Q3 transition of Phosphatidyl
choline was compared with the ones in the sample (m/z 184.07,
185.07, 786.59, 787.60, 788.60).
(TIF)
Figure S3 Validation of Phosphatidyl ethanolamine in
the sample by MS/MS. Candidate marker was validated by
UPLC-TOF-MS/MS. Q1 to Q3 transition of Phosphatidyl
ethanolamine was compared with the ones in the sample (m/z
184.07, 185.07, 772.58).
(TIF)
Figure S4 Validation of Arachidonic acid in the sample
by MS/MS Validation of metabolites in the sample by
MS/MS. Candidate marker was validated by UPLC-TOF-MS/
MS. Q1 to Q3 transition of Arachidonic acid was compared with
the ones in the sample (m/z 259.24, 303.23).
(TIF)
Table S1 Random Forests top 50 metabolite putative
identity lists in positive ionization mode.
(DOCX)
Table S2 Random Forests top 50 metabolite putative
identity lists in negative ionization mode.
(DOCX)
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